Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
European Journal of Haematology|January 15, 2026
Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal ImpairmentRintu Sharma, Eshetu G Atenafu, Esther Masih-Khan, et al.
Leukemia & Lymphoma|June 20, 2018
A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)Christine I Chen, Harminder Paul, Lisa W Le, et al.
Blood Cancer Journal|March 22, 2019
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studySuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 9, 2012
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myelomaSundar Jagannath, Ravi Vij, A Keith Stewart, et al.
British Journal of Haematology|June 19, 2013
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agentsChristine I Chen, Esther Masih-Khan, Haiyan Jiang, et al.
Leukemia|July 16, 2020
The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myelomaJoseph Longo, Petr Smirnov, Zhihua Li, et al.
Cancer Research|May 6, 2004
Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivoYoung Trieu, Xiao-Yan Wen, Brian F Skinnider, et al.
Leukemia & Lymphoma|October 3, 2018
A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL)Christine I Chen, Harminder Paul, Susi Snitzler, et al.
Haematologica|August 28, 2025
Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myelomaHanny Musa, Michał Mielnik, Suzanne Trudel, et al.
Blood Cancer Discovery|March 11, 2026
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed Refractory Multiple MyelomaRintu Sharma, Andree-Anne Pelland, Katherine Lajkosz, et al.
Pageof 11